In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including:<ul><li>Rationale for targeting CELMoDs in NHL</li><li>Mechanism of action of CELMoDs</li><li>Key studies and available efficacy and safety data with investigational CELMoDs in NHL</li><li>Key ongoing clinical trials of CELMoDs in NHL</li><li>Strategies to boost NHL clinical trial diversity among underserved communities</li></ul>Presenters: Julio C. Chavez, MD, MS Associate Member Department of Malignant Hematology ICE-T Clinical Research Medical Director for Hematologic Malignancies H. Lee Moffitt Cancer Center and Research Institute Associate Professor University of South Florida Tampa, FloridaAlan Skarbnik, MD Director, Lymphoma and CLL Program Director, Immune Effector Cell Therapeutics Program Novant Health Cancer Institute Charlotte, North CarolinaContent based on an online CME program supported by educational grants from Bristol-Myers Squibb.Link to full program: <a href="https://bit.ly/45YXoZI" target="_blank">https://bit.ly/45YXoZI</a>

Clinical Care Options

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies

cco oncology podcast

CCO Oncology Podcast

Listen to Julio C. Chavez, MD, MS, a medical oncologist based in an academic center, and Alan Skarbnik, MD, a medical oncologist based in the community, discuss the emerging role of CELMoDs in non-Hodgkin lymphoma care, including available data and ongoing clinical trials with these agents.

Episode Summary

Clips